TABLE I.
Immune checkpoint inhibitors of interest in genitourinary malignancies
| Drug | Target |
|---|---|
| Atezolizumab | PD-L1 |
| Avelumab | PD-L1 |
| Durvalumab | PD-L1 |
| Ipilimumab | CTLA-4 |
| Nivolumab | PD-1 |
| Pembrolizumab | PD-1 |
| Tremelimumab | CTLA-4 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.